571 related articles for article (PubMed ID: 29852973)
21. Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials.
Giugliano D; Maiorino MI; Longo M; Bellastella G; Chiodini P; Esposito K
Endocrine; 2019 Jul; 65(1):15-24. PubMed ID: 31028667
[TBL] [Abstract][Full Text] [Related]
22. Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN-HF study.
Correale M; Antohi EL; Inciardi RM; Mazzeo P; Coiro S; Ishihara S; Petroni R; Monitillo F; Leone M; Triggiani M; Sarwar CMS; Dungen HD; Talha KM; Brunetti ND; Butler J; Nodari S;
ESC Heart Fail; 2023 Jun; 10(3):2066-2073. PubMed ID: 36924023
[TBL] [Abstract][Full Text] [Related]
23. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
Kohsaka S; Lam CSP; Kim DJ; Cavender MA; Norhammar A; Jørgensen ME; Birkeland KI; Holl RW; Franch-Nadal J; Tangri N; Shaw JE; Ilomäki J; Karasik A; Goh SY; Chiang CE; Thuresson M; Chen H; Wittbrodt E; Bodegård J; Surmont F; Fenici P; Kosiborod M;
Lancet Diabetes Endocrinol; 2020 Jul; 8(7):606-615. PubMed ID: 32559476
[TBL] [Abstract][Full Text] [Related]
24. Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis.
Wei W; Liu J; Chen S; Xu X; Guo D; He Y; Huang Z; Wang B; Huang H; Li Q; Chen J; Chen H; Tan N; Liu Y
Front Endocrinol (Lausanne); 2022; 13():850836. PubMed ID: 35330914
[TBL] [Abstract][Full Text] [Related]
25. Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study.
Nair R; Mody R; Yu M; Cowburn S; Konig M; Prewitt T
Diabetes Ther; 2022 Dec; 13(11-12):1921-1932. PubMed ID: 36131064
[TBL] [Abstract][Full Text] [Related]
26. Sodium-Glucose Cotransport Protein 2 Inhibitors in Patients With Type 2 Diabetes and Acute Kidney Disease.
Pan HC; Chen JY; Chen HY; Yeh FY; Huang TT; Sun CY; Wang SI; Wei JC; Wu VC
JAMA Netw Open; 2024 Jan; 7(1):e2350050. PubMed ID: 38170522
[TBL] [Abstract][Full Text] [Related]
27. Renoprotective effect of SGLT-2 inhibitors among type 2 diabetes patients with different baseline kidney function: a multi-center study.
Lin FJ; Wang CC; Hsu CN; Yang CY; Wang CY; Ou HT
Cardiovasc Diabetol; 2021 Oct; 20(1):203. PubMed ID: 34620182
[TBL] [Abstract][Full Text] [Related]
28. Association of SGLT-2 Inhibitors With Treatment Satisfaction and Diabetes-Specific and General Health Status in Adults With Cardiovascular Disease and Type 2 Diabetes.
Ding Q; Spatz ES; Bena JF; Morrison SL; Levay M; Lin H; Grey M; Edwards NE; Isaacs D; West L; Combs P; Albert NM
J Am Heart Assoc; 2023 Sep; 12(17):e029058. PubMed ID: 37655510
[TBL] [Abstract][Full Text] [Related]
29. Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age <65 with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction: A Cost-Benefit Analysis.
Glover S; Borrego ME; Ray GM; Roberts MH
Clinicoecon Outcomes Res; 2022; 14():465-477. PubMed ID: 35845354
[TBL] [Abstract][Full Text] [Related]
30. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
Heerspink HJL; Karasik A; Thuresson M; Melzer-Cohen C; Chodick G; Khunti K; Wilding JPH; Garcia Rodriguez LA; Cea-Soriano L; Kohsaka S; Nicolucci A; Lucisano G; Lin FJ; Wang CY; Wittbrodt E; Fenici P; Kosiborod M
Lancet Diabetes Endocrinol; 2020 Jan; 8(1):27-35. PubMed ID: 31862149
[TBL] [Abstract][Full Text] [Related]
31. Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A meta-analysis of cardiovascular outcome trials.
Singh AK; Singh R
Diabetes Res Clin Pract; 2021 Feb; 172():108648. PubMed ID: 33421444
[TBL] [Abstract][Full Text] [Related]
32. Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients With Type 2 Diabetes and the Incidence of Retinal Vein Occlusion in Taiwan.
Tsai HR; Lin YJ; Yeh JI; Lin SM; Liu PP; Chang YC; Lee YC; Loh CH; Huang HK
Invest Ophthalmol Vis Sci; 2024 Jun; 65(6):19. PubMed ID: 38864813
[TBL] [Abstract][Full Text] [Related]
33. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
Nassif ME; Kosiborod M
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():19-23. PubMed ID: 31081589
[TBL] [Abstract][Full Text] [Related]
34. Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus.
Eroglu TE; Coronel R; Zuurbier CJ; Blom M; de Boer A; Souverein PC
Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):18-25. PubMed ID: 35894858
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes.
Dawwas GK; Smith SM; Park H
Diabetes Obes Metab; 2019 Jan; 21(1):28-36. PubMed ID: 30039524
[TBL] [Abstract][Full Text] [Related]
36. Evolving channeling in prescribing SGLT-2 inhibitors as first-line treatment for type 2 diabetes.
Shin H; Schneeweiss S; Glynn RJ; Patorno E
Pharmacoepidemiol Drug Saf; 2022 May; 31(5):566-576. PubMed ID: 34985178
[TBL] [Abstract][Full Text] [Related]
37. SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?
Al Rifai M; Newby LK; Nair AP; Misra A; Rogers JG; Fedson S; Virani SS
Curr Atheroscler Rep; 2022 Aug; 24(8):627-634. PubMed ID: 35653033
[TBL] [Abstract][Full Text] [Related]
38. Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.
Hinton W; Feher MD; Munro N; Joy M; de Lusignan S
Cardiovasc Diabetol; 2021 Jun; 20(1):130. PubMed ID: 34183018
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study.
Østergaard HB; Humphreys V; Hengeveld EM; Honoré JB; Mach F; Visseren FLJ; Westerink J; Yadav G; Mosenzon O;
Diabetes Obes Metab; 2023 Feb; 25(2):435-443. PubMed ID: 36199242
[TBL] [Abstract][Full Text] [Related]
40. Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Zhang A; Luo X; Meng H; Kang J; Qin G; Chen Y; Zhang X
Front Endocrinol (Lausanne); 2020; 11():604250. PubMed ID: 33519713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]